Tag: Lung Cancer
OncoHost Collaborates with Lung Biobank Heidelberg to Discover Lung Cancer Biomarkers
OncoHost, a global leader in next-generation precision oncology for improved personalized cancer therapy, recently announced a research collaboration with Lung Biobank Heidelberg, a member of BioMaterialBank Heidelberg (BMBH) and the German Center for Lung Research (DZL). The collaboration involves the systematic...
Biodesix to Collaborate with Datavant to Boost Value of Lung Cancer Databank
Biodesix, Inc. (Nasdaq: BDSX), a leading lung cancer diagnostic solutions company, announced a strategic partnership with Datavant, a leader in helping healthcare organizations safely connect their data. Datavant provides solutions to help protect, match, and share health data. Through this partnership, Biodesix...
Neutrophil Defensin Expression Correlated With Immune Checkpoint Response In Lung Cancer
Lung cancer is the leading cause of cancer related death. Non-small cell lung cancer (NSCLC), comprises 80–85% of all lung cancer cases. Programmed cell death ligand 1 (PDL1) is an approved immunotherapeutic target in lung cancer patients. PDL1 expression...
CLOVER Study Of PDL1 In NSCLC Demonstrates PCR RNA Expression Analysis Not Equivalent To...
Programmed cell death ligand 1 (PDL1) is approved therapeutic target in lung cancer patients. PDL1 expression above a set threshold must be confirmed by companion immunohistochemistry (IHC) test in order for the patient to be eligible for PDL1 checkpoint...
A Living Biobank Of Non-Small Cell Lung Cancer Organoids
Globally, cancer of the lung is the most common cause of
cancer related mortality. It is also the most commonly diagnosed. 3D patient derived
organoids provide a more faithful model of cancer than 2D in vitro cell
culture and represent a model...
Biobank Study Of Functional Lung Impairment And Lung Cancer Risk
Globally, cancer of the lung is the most common cause of
cancer related mortality. It is also the most commonly diagnosed. Tobacco smoke
is a well-known risk factor for the development of lung cancer. Smoking leads
to lung impairment and conditions such...
Veracyte Makes Progress With Development Of Nasal Swab Test For Early Lung Cancer Detection
Veracyte, Inc. has announced preliminary clinical data
showing that the company’s non-invasive nasal swab test – the first of its kind
– can enable early lung cancer detection and diagnosis so that more lives can
be saved. The new findings specifically show...
Veracyte Releases Percepta® Genomic Sequencing Classifier For Lung Cancer Diagnosis
Veracyte, Inc., a leading genomic diagnostics company, has
begun making its next-generation Percepta® Genomic Sequencing Classifier (GSC)
available to physicians, providing them with expanded lung cancer risk information
that can further guide next steps for patients with suspicious lung nodules, as
compared to...
Veracyte and Johnson & Johnson Collaborate To Pool Resources For The Lung Cancer Initiative
Veracyte, Inc. has announced that it has entered into a
long-term strategic collaboration with Johnson & Johnson Innovation LLC (Johnson
& Johnson Services, Inc.) and the Lung Cancer Initiative at Johnson &
Johnson to advance the development and commercialization of novel diagnostic
tests...
